Image source: Getty Images.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is best known for Eylea. The drug, which is used to treat three eye diseases, generated $3.1 billion in 2015 for Regeneron and nearly $950 million for the biotech’s partner, Bayer.